Search over 3,000 reports

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2017

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 84
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0142
    DelveInsight's, "Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this mechanism of action. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. This report provides information on the therapeutic development based on the Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also provides information on pan Fibroblast Growth Factor Receptor (1-4) Inhibitors. The report covers the company's information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. The report covers 15 drugs.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
    Overview
    Total Products Overview
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I)
    Discovery and Pre-clinical stage Products
    Therapeutic Assessment - Active Products
    Assessment by Monotherapy Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Dormant Products
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Mid Stage Products (Phase II)
    Early stage Products
    Therapeutic Assessment - Active Products
    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Recent Updates
    Companies Involved in Therapeutic Development
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1:Total Products for FGFR-4 Inhibitors and Pan FGFR (1-4) Inhibitors
    Table 2: Number of Products Under Development for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
    Table 3: Number of Products under Development by Companies
    Table 4: Mid Stage Products (Phase II)
    Table 5: Early Stage Products (Phase I)
    Table 6: Discovery and Pre-clinical Stage Products
    Table 7: Assessment by Monotherapy Products for FGFR-4 Inhibitors
    Table 8: Assessment by Route of Administration for FGFR-4 Inhibitors
    Table 9:Assessment by Stage and Route of Administration for FGFR-4 Inhibitors
    Table 10: Assessment by Molecule Type for FGFR-4 Inhibitors
    Table 11: Assessment by Stage and Molecule Type for FGFR-4 Inhibitors
    Table 12: Dormant Products
    Table 13: Number of Products Under Development for Pan Fibroblast Growth Factor Receptor (1-4) Inhibitors
    Table 14: Number of Products under Development by Companies
    Table 15: Mid Stage Products
    Table 16: Early Stage Products
    Table 17: Assessment by Monotherapy Products for Pan FGFR (1-4) Inhibitor
    Table 18: Assessment by Route Of Administration for Pan FGFR (1-4) Inhibitor
    Table 19: Assessment by Stage and Route of Administration for Pan FGFR (1-4) Inhibitor
    Table 20: Assessment by Molecule Type for Pan FGFR (1-4) Inhibitor
    Table 21: Assessment by Stage and Molecule Type for Pan FGFR (1-4) Inhibitor
    Table 22: Astellas Pharma Inc.
    Table 23: AstraZeneca plc
    Table Continued?.
    Table 33:Principia Biopharma
    Figure 1: Schematic Representation of Fibroblast Growth Factor Receptor
    Figure 2: Fibroblast Growth Factor Receptors 4 (FGFR4) Mechanism Of Action
    Figure 3: Fibroblast Growth Factor Receptors 4 (FGFR4) in Hepatocellular Carcinoma
    Figure 4: Total Products for FGFR-4 Inhibitors and Pan FGFR (1-4) Inhibitors (%)
    Figure 5: Number of Products under Development for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
    Figure 6: Mid Stage Products (Phase II)
    Figure 7: Early Stage Products (Phase I)
    Figure 8: Discovery and Pre-clinical Stage Products
    Figure 9: Assessment by Monotherapy Products for FGFR-4 Inhibitors
    Figure 10: Assessment by Route of Administration for FGFR-4 Inhibitors
    Figure 11: Assessment by Stage and Route of Administration for FGFR-4 Inhibitors
    Figure 12: Assessment by Molecule Type for FGFR-4 Inhibitors
    Figure 13: Assessment by Stage and Molecule Type for FGFR-4 Inhibitors
    Figure 14: Dormant Products
    Figure 15: Number of Products under Development for Pan Fibroblast Growth Factor Receptor (1-4) Inhibitors
    Figure 16: Mid Stage Products
    Figure 17: Early Stage Products
    Figure 18: Assessment by Monotherapy Products for Pan FGFR (1-4) Inhibitor
    Figure 19: Assessment by Route of Administration for Pan FGFR (1-4) Inhibitor
    Figure 20: Assessment by Stage and Route of Administration for Pan FGFR (1-4) Inhibitor
    Figure 21: Assessment by Molecule Type for Pan FGFR (1-4) Inhibitor
    Figure 22:Assessment by Stage and Molecule Type for Pan FGFR (1-4) Inhibitor
    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Pipeline Drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Pipeline Assessment

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Pipeline Analysis

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Drugs under Development

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Discovery drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Preclinical drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Phase I drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Phase II drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Phase III Pipeline Drugs Assessment

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Preregistration drugs

    Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Molecules in pipeline

    • Single User License
      (20% Off)
      $1,250.00
      $1000
    • Site License
      (30% Off)
      $2,500.00
      $1750
    • Global License
      (40% Off)
      $4,000.00
      $2400

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap